Nasdaq
$35.72▲ 0.15%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $4.45BShares out 1.200M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
29- 9.30Overnight26.09.30 10:154Ownership#●●●
Definium Therapeutics, Inc.
Insider Karlin Daniel of Definium Therapeutics, Inc. reported a change in beneficial ownership of securities as of September 25, 2026. This filing serves as a Form 4 statement regarding the insider's equity holdings.…more
$35.72+0.15%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.30Overnight26.09.30 10:144Ownership
Definium Therapeutics, Inc.
Insider Robert Barrow of Definium Therapeutics, Inc. reported a change in beneficial ownership of securities as of September 25, 2026. This filing serves as a formal disclosure of insider equity movement via Form 4.…more
$35.72+0.15%vs prev closeView filingShare - 9.30Overnight26.09.30 10:124Ownership
Definium Therapeutics, Inc.
Definium Therapeutics, Inc. insider Matthew T. Wiley filed a Form 4 on September 29, 2026, reporting a change in beneficial ownership of securities as of September 25, 2026. This filing serves as an official disclosure of the insider's equity transaction to the SEC.…more
$35.72+0.15%vs prev closeView filingShare
28 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.14Regular26.09.15 00:13Bullish#●●●#●●●#●●●
Definium Reports Successful Phase 3 Results for Anxiety Drug
Definium's anxiety treatment DT120 met its primary endpoint in a Phase 3 study, demonstrating statistically significant symptom improvement compared to placebo. The company plans to move forward with an NDA submission following these positive clinical results.…more
$35.72+0.15%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.14Pre-market26.09.14 20:25
●●●●●●●● ●●●●● ●●●●●●
The trading halt for Definium Therapeutics (DFTX) has been lifted and trading has resumed. Information regarding the halt status and the resumption time has been updated.…more
$35.72+0.15%vs prev closeShareBenzinga - 9.14Pre-market26.09.14 20:03
●●●●●●●● ●●●●● ●●●●●●
Definium Therapeutics reported that its Phase 3 Panorama study for DT120 in generalized anxiety disorder met all primary and key secondary efficacy endpoints. The company plans to proceed with a pre-NDA meeting in late 2026 and expects to file for regulatory approval in the first half of 2027.…more
$35.72+0.15%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report